Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.66 |
| ▸ | HTR2A | P28223 | 18/20 | 0.66 |
| ▸ | HTR2B | P41595 | 17/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095360 | 1.00 | HTR2C (0.66) | HTR2CHTR2AHTR2BADRA2AADRA2B | |
| SCHEMBL1095359 | 1.00 | HTR2C (0.66) | HTR2CHTR2AHTR2BADRA2AADRA2B | |
| SCHEMBL1096662 | 0.85 | HTR2A (0.66) | HTR2CHTR2AHTR2BADRA2AADRA2B | |
| SCHEMBL1095337 | 0.85 | HTR2C (0.73) | HTR2CHTR2AHTR2B | |
| SCHEMBL1096554 | 0.85 | HTR2C (0.73) | HTR2CHTR2AHTR2B | |
| SCHEMBL1095335 | 0.85 | HTR2C (0.73) | HTR2CHTR2AHTR2B | |
| SCHEMBL1095023 | 0.85 | HTR2A (0.66) | HTR2CHTR2AHTR2BADRA2AADRA2B | |
| SCHEMBL1096664 | 0.85 | HTR2A (0.66) | HTR2CHTR2AHTR2BADRA2AADRA2B | |
| SCHEMBL13679042 | 0.85 | HTR2C (0.52) | HTR2CHTR2AHTR2B | |
| SCHEMBL1097029 | 0.80 | HTR2C (1.00) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012495-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | claimed |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | ARENA PHARMACEUTICALS, A DELAWARE CORPORATION | 2007-03-15 | — | — | US | claimed |
| EP-1411881-B9 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2006-11-15 | — | — | EP | claimed |
| EP-1557409-A1 | 5HT2C receptor modulators | Arena Pharmaceuticals, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1411881-B1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2005-05-04 | — | — | EP | claimed |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | claimed |
| EP-1411881-A4 | 5HT sb 2C /sb RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2004-07-07 | — | — | EP | claimed |
| EP-1411881-A2 | 5HT sb 2C /sb RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| US-20030225057-A1 | 3-Benzoazepine derivatives | ARENA PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | claimed |
| WO-2003086306-A2 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1411881-A4 | 5HT sb 2C /sb RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1411881-A2 | 5HT sb 2C /sb RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030225057-A1 | 3-Benzoazepine derivatives | ARENA PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003086306-A2 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225057-A1 | 3-Benzoazepine derivatives | HTR2C, HTR1A, HTR3A | HTR2C 1/4885HTR2A 13/4885HTR2B 10/4885 |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2A 7/4885HTR2B 14/4885 |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | HTR2C, HTR3B, HTR3C | HTR2C 1/4885HTR2A 8/4885HTR2B 6/4885 |
| US-20130012495-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885 |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.